Merus regains some lost pride while Bicycle rides to even greater heights.
Moderna is the standout gainer, but the stragglers are becoming more apparent as the pandemic tide retreats.
A strong performance from a handful of large drug developers could not rescue the sector from a weak three months on the stock market.
Meanwhile long-term efficacy of the Pfizer and Moderna jabs largely holds up, though J&J’s data seems less convincing.
Valneva might have to look beyond the UK for vaccine sales after today's contract termination.
A project from SK Bioscience and Glaxo started phase 3 this week, but it is far from the only late-stage candidate.
Despite unconvincing results so far with next-gen IL-2 agents, plenty of groups are still crowding into this space.